Opinion|Videos|November 27, 2024
Real-World Outcomes in HER2-Positive NSCLC
Key Takeaways
- Real-world outcomes for HER2-positive NSCLC differ from clinical trials due to diverse patient populations and treatment settings.
- Clinical trials involve selected patients, while real-world settings include those with comorbidities and varying performance statuses.
Dr Heymach real-world outcomes versus clinical trials for HER2-positive NSCLC and the management of common adverse events associated with HER2-directed therapies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do real-world patient outcomes for patients with HER 2 positive NSCLC compare to those seen in clinical trials?
- What are the most common treatment-related adverse events observed with HER2-directed therapies, and how are they managed?
Advertisement
Related to this article
SaTScan detects an acute HCV outbreak cluster in California, showing the potential of automated surveillance, though real-time testing is needed.
Genetic analysis finds 125 loci shared by insomnia and CRP, with Mendelian randomization favoring an effect from insomnia liability to inflammation.
Proinflammatory diets were tied to higher mortality in MASLD and MetALD, whereas antioxidant-rich diets tracked with better survival.
An analysis finds distinct adverse event reporting patterns across immunosuppressive regimens, highlighting the need for tailored safety monitoring.
Sjögren disease involves far more than dry eyes and mouth, and variable symptoms plus multispecialty testing delay diagnosis, says Steven Carsons, MD.
Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
Admilparant 60 mg met the ALOFT-IPF primary end point, significantly improving FVC change vs placebo at 52 weeks in idiopathic pulmonary fibrosis.
Advertisement
Advertisement